期刊文献+

异基因造血干细胞移植后共刺激分子LIGHT/HVEM的表达与GVHD的关系 被引量:3

The expression of LIGHT and HVEM in T lymphocytes post aIIo-HSCT and its relation to the development of GVHD
原文传递
导出
摘要 目的探讨异基因造血干细胞移植(allo-HSCT)后共刺激分子LIGHT和HVEM的表达与移植物抗宿主病(GVHD)发生的关系。方法26例allo-HSCT患者中,预处理方案采用环磷酰胺+足叶乙甙+全身照射11例,采用氟达拉滨+阿糖胞苷+白消安12例,采用环磷酰胺3例。移植时,输注单个核细胞(5.89±3.36)×10^8/kg,CD34^+细胞(3.29±1.29)×10^6/kg。预防急性GVHD(aGVHD)的方案采用环孢素A+短程甲氨蝶呤+吗替麦考酚酯,HLA半相合及非血缘关系者加用抗胸腺细胞球蛋白。GVHD的诊断与分级采用西雅图标准。在预处理前、移植后15d、发生aGVHD时及aGVHD经治疗好转后分别采集患者外周血2ml,采用三色流式细胞术进行检测,同时以15名健康志愿者的血液标本作为正常对照。结果所有患者均获得造血功能重建,移植物均完全植活。移植后共发生aGVHD9例,发生率为35%,其中Ⅲ~Ⅳ度者3例,8例经治疗后好转,1例治疗无效死亡;发生慢性GVHD(cGVHD)7例,发生率为26.9%。患者预处理前和移植后15d及正常人外周血T淋巴细胞几乎不表达LIGHT,组成性表达HVEM;发生GVHD时,LIGHT表达显著上调,HVEM表达下调;GVHD好转后,LIGHT和HVEM的表达恢复正常。移植后158时,发生aGVHD者LIGHT的表达高于未发生aGVHD者,而HVEM的表达较低(P〈0.05)。Ⅲ~Ⅳ度aGVHD者LIGHT的表达明显高于I~II度者(P〈0.05)。结论LIGHT/HVEM在allo-HSCT后GVHD的发生和发展过程中起重要作用,通过监测该共刺激分子的表达对aGVHD的发生有一定预示作用。 Objective To explore the relationship between the expression of LIGHT/HVEM in patients after allo-HSCT and the development of GVHD. Methods The expression of LIGHT and HVEM in T lymphocytes was detected by FACS Calibur. Results All patients achieved engraftment and hematopoiesis reconstitution, aGVHD occurred in 9 of 26 patients (34. 6 %) with grade III-IV aGVHD in 3 cases. Seven cases developed cGVHD (26. 9 % ). LIGHT was not expressed in T lymphocytes from healthy donors and patients without GVHD, while constitutive expression of HVEM was detected. When aGVHD occurred, the expression levels of LIGHT in T lymphocytes were significantly increased, while those of HVEM decreased. After GVHD was controlled, the expression levels of those co-stimulators went back to normal. On the day 15 after transplantation, the expression of LIGHT in T lymphoeytes of patients with aGVHD later was significantly higher, while that of HVEM lower than in those without aGVHD. The patients with aGVHD of grades III-IV demonstrated higher LIGHT expression than in those with aGVHD of grades I - II. Conclusion The expression of LIGHT and HVEM might be involved in the development of GVHD after aIlo-HSCT and could be used as one of the'useful indicators in predicting aGVHD.
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2010年第2期89-92,共4页 Chinese Journal of Organ Transplantation
基金 国家自然科学基金(30172347,308711002) 上海市生物医药重大科技攻关项目(05DZ19327)
关键词 造血干细胞移植 受体 肿瘤坏死因子 成员14 移植物抗宿主病 Hematopoietic stem cell transplantation Receptors, tumor necrosis factor, member 14 Graft versus host disease
  • 相关文献

参考文献6

  • 1Granger SW, Richert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev, 2003, 14(3-4) : 289-296.
  • 2Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol, 2003, 3(8): 609-620.
  • 3Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med, 2000, 6(3):283-289.
  • 4Tamada K, Tamura H, Flies D, et al. Blockade of LIGHT/ LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest, 2002, 109 (4) : 549-557.
  • 5Xu Y, Flies AS, Flies DB, et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood, 2007, 1119(9): 4097-4104.
  • 6Brown GR, Lane GW, Whittington BJ. Disparate role of LIGHT in organ-specific donor T cells activation and effector molecules in MHC class Ⅱ disparate GVHD. J Clin Immunol, 2009 Oct 14. [Epub ahead of print].

同被引文献52

  • 1Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HI,A-identical transplants in leukemia[ J]. Blood, 1991,78 ( 8 ) : 2120-2130.
  • 2Sistigu A, Viaud S, Chaput N, et al. hnmunomodulatory effects of cyclophosphamide and implementations for vaccine design [ J ]. Semin Immunopathol,2011,33(4) :369-383.
  • 3Shukla S, Mehta A, John J, et al. Immunomodulatory activities of the ethanolic extract of Caesalpinia bonducella seeds[J]. J Ethno- pharmaco1,2009,125 ( 2 ) :252-256.
  • 4Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tis- sue xenografts in immunodeficient mice: a systematic review [ J ]. Clin Transl Onco1,2010,12 ( 7 ) :473-480.
  • 5Imataki O, Ohnishi H, Ohbayashi Y, et al. Fludarabine and mel- phalan conditioning with tacrolimus as GVHD prophylaxis for allo- geneic stem cell transplant recipients is an effective reduced-inten- sity combination regimen compared to the conventional regimen [ J ]. Int J Clin Onco1,2009,14 (3) : 197-201.
  • 6Luznik L, Bolaos-Meade J, Zahurak M, et al. High-dose cyclo- phosphamide for graft-versus-host disease prevention [ J ]. Curr Opin Hematol,2010,17(6) :493-499.
  • 7Luznik L, Zahurak M, Chen AR, et al. High-dose cyclophospha- mide as single-agent, short-course prophylaxis of graft-versus-host disease[ J]. Blood,2010,115 (16) :3224-3230.
  • 8Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self- tolerance maintained by activated T ceils expressing IL-2 receptoralpha-chains (CD25). Breakdown of a single mechanism of self- tolerance causes various autoimmune diseases [ J]. J Immunol, 2011,186(7) :3808-3821.
  • 9Sakaguchi S. Naturally arising CD4 + regulatory t cells for immu- nologic self-tolerance and negative control of immune responses [J]. Annu Rev Immunol,2004 ,22 :531-562.
  • 10Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance [ J ]. Ce11,2008,133 ( 5 ) :775-787.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部